Pricing Log in Create free account

Mesoblast Limited (MESO) vs Ultragenyx Pharmaceutical Inc. (RARE)

Mesoblast Limited and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Mesoblast Limited and Ultragenyx Pharmaceutical Inc. are of similar size ($1.7B and $1.7B). Ultragenyx Pharmaceutical Inc. grew revenue faster over the last twelve months: 15.8% against −26.5%. Ultragenyx Pharmaceutical Inc. has the higher net margin (−71.7% vs −1,091.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Mesoblast Limited leads on 8 and Ultragenyx Pharmaceutical Inc. on 8.

Valuation

Metric MESO RARE Biotechnology median
P/E n/m n/m 11.36
P/S 136.96 2.25 9.12
P/B 1.79 n/m 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m n/m 0.62
EV/Sales 136.55 1.89 8.56
Earnings yield (8.48%) (32.17%) (34.18%)
Free cash flow yield (8.21%) (27.15%) (23.62%)

Profitability

Metric MESO RARE Biotechnology median
Gross margin (269.72%) 82.88% 67.24%
Operating margin (826.28%) (63.98%) 0.00%
Net margin (1,091.71%) (71.72%) 0.00%
Free cash flow margin 0.00% (61.20%) 0.00%
Return on equity 0.00% 285.46% (50.28%)
Return on assets 0.00% (44.05%) (45.89%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MESO RARE Biotechnology median
Revenue growth (TTM) (26.54%) 15.78% 6.96%
EPS growth (last fiscal year) 48.24% 7.31% 29.86%
Revenue growth, 5-year CAGR 74.39% 19.95% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO RARE Biotechnology median
Debt to equity 0.22 0.00 0.00
Current ratio 1.58 1.40 4.72
Net debt to EBITDA (0.67) 1.35 1.01

Dividend

Metric MESO RARE Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric MESO RARE Biotechnology median
Market cap 1.70b 1.66b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack